These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38631985)

  • 1. [Epcoritamab - relapsed or refractory large diffuse B cells lymphoma after two or more lines of systemic therapy].
    Bensaber H; Cacheux V
    Bull Cancer; 2024 Jun; 111(6):544-545. PubMed ID: 38631985
    [No Abstract]   [Full Text] [Related]  

  • 2. [Glofitamab in relapsed and/or refractory diffuse large B cell lymphoma after at least two lines of treatment].
    Daguerre V; Croizier C
    Bull Cancer; 2024 Sep; 111(9):794-796. PubMed ID: 38876895
    [No Abstract]   [Full Text] [Related]  

  • 3. [New drug approval : Loncastuximab tesirine in diffuse large B-cell lymphoma relapsed/refractory after two lines of treatment].
    Tauveron-Jalenques U; Bay JO
    Bull Cancer; 2023 May; 110(5):476-477. PubMed ID: 36949000
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
    Rosenthal A; Munoz J; Jun M; Wang T; Mutebi A; Wang A; Yang S; Osei-Bonsu K; Elliott B; Rivas Navarro F; Yu J; Brodkin S; Sacchi M; Ip A
    J Hematol Oncol; 2024 Aug; 17(1):69. PubMed ID: 39152509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment].
    Chiche E; Loschi M
    Bull Cancer; 2022 Sep; 109(9):879-880. PubMed ID: 35717220
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma].
    Chanut M; Herbaux C
    Bull Cancer; 2023 Oct; 110(10):986-988. PubMed ID: 37661551
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Phillips T; Brunvand M; Chen AI; Essell J; Chiappella A; Diefenbach C; Cheng J; Ramies D; Hirata J; Morschhauser F; Flinn IW
    Am J Hematol; 2022 Jan; 97(1):E24-E27. PubMed ID: 34731510
    [No Abstract]   [Full Text] [Related]  

  • 11. A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokineinduced killer cells: a first-in-human case report.
    Elice F; Sommaggio R; Cappuzzello E; Riva M; Tisi MC; Bernardi M; Bozza A; Catanzaro D; Chieregato K; Merlo A; Giaretta I; Pieta AD; Krampera M; Visco C; Trentin L; Visentin A; Tosetto A; Astori G; Rosato A
    Haematologica; 2024 Sep; 109(9):3037-3041. PubMed ID: 38721751
    [No Abstract]   [Full Text] [Related]  

  • 12. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
    van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
    Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy.
    Yi JH; Kim SJ; Ko YH; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):317-20. PubMed ID: 21067447
    [No Abstract]   [Full Text] [Related]  

  • 15. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
    Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
    Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term results of rituximab-based salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma].
    Wang XX; Huang HQ; Xia ZJ; Lin XB; Cai QQ; Gao Y; Lin ZX; Lin TY; Jiang WQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):867-70. PubMed ID: 20423868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ring-shaped lesions on a lung scan].
    Coşkuntürk M; Aarntzen EHJG; van der Velden WJFM
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30719883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.
    Jurczak W; Bryk AH; Mensah P; Gałązka K; Trofimiuk-Müldner M; Wyrobek Ł; Sawiec A; Skotnicki AB
    J Med Case Rep; 2016 May; 10(1):123. PubMed ID: 27178351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.